SMO Clinplus Co

SMO Clinplus Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SMO Clinplus Co (301257.SZ) as of Nov 4, 2026 is 25.41 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -9.67 % — a change of -362.81% (higher).

FCF Conversion

25.41 %

YoY

-362.81%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SMO Clinplus Co is 2025 25.41 % . FCF Conversion Rate (FCF/EBITDA) of SMO Clinplus Co was 2024 -9.67 % . It decreases by -362.81% higher compared to the previous year.

The SMO Clinplus Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
77.59 CNY
Jan 1, 2020
52.00 CNY
Jan 1, 2021
64.24 CNY
Jan 1, 2022
44.86 CNY
Jan 1, 2023
77.64 CNY
Jan 1, 2024
-9.67 CNY
Jan 1, 2025
25.41 CNY
The SMO Clinplus Co FCF Conversion history
YEARFCF ConversionYoY
25.41 %-362.81%
-9.67 %-112.45%
77.64 %+73.07%
44.86 %-30.17%
64.24 %+23.56%
52.00 %-32.98%
77.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SMO Clinplus Co Stock analysis

What does SMO Clinplus Co do? SMO ClinPlus Co., Ltd. generates revenue by offering site management organization (SMO) services for clinical research and development to pharmaceutical companies, medical device companies, and health-related product developers. The company provides comprehensive services including pre-preparation planning, site start-up, on-site execution, and full-process project management. Its primary clients are domestic and foreign pharmaceutical firms, medical device manufacturers, and health product R&D entities operating in both domestic and international markets. The firm's service model focuses on supporting clinical trials through end-to-end management, targeting companies engaged in drug development and medical device testing. By delivering tailored SMO solutions, SMO ClinPlus serves the needs of clients requiring efficient site management for their clinical research activities. The company's operations span across domestic and overseas markets, serving a broad range of healthcare industry participants. SMO Clinplus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SMO Clinplus Co stock

FCF Conversion Rate (FCF/EBITDA) of SMO Clinplus Co is 25.41 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of SMO Clinplus Co changed from -9.67 % to 25.41 %, representing a -362.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SMO Clinplus Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SMO Clinplus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SMO Clinplus Co

All Key Metrics — SMO Clinplus Co